Last reviewed · How we verify

Biological: AZD3152

AstraZeneca · Phase 2 active Biologic

Biological: AZD3152 is a PD-1/PD-L1 inhibitor Biologic drug developed by AstraZeneca. It is currently in Phase 2 development for Non-small cell lung cancer, Head and neck squamous cell carcinoma.

AZD3152 is a monoclonal antibody targeting PD-L1.

AZD3152 is a monoclonal antibody targeting PD-L1. Used for Non-small cell lung cancer, Head and neck squamous cell carcinoma.

Likelihood of approval
16.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Oncology Phase 2 attrition -2.0pp
    Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
  • Big-pharma sponsor +3.0pp
    AstraZeneca is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameBiological: AZD3152
SponsorAstraZeneca
Drug classPD-1/PD-L1 inhibitor
TargetPD-L1
ModalityBiologic
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

AZD3152 works by binding to PD-L1, preventing its interaction with PD-1 and thereby enhancing T-cell mediated anti-tumor immune response.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Biological: AZD3152

What is Biological: AZD3152?

Biological: AZD3152 is a PD-1/PD-L1 inhibitor drug developed by AstraZeneca, indicated for Non-small cell lung cancer, Head and neck squamous cell carcinoma.

How does Biological: AZD3152 work?

AZD3152 is a monoclonal antibody targeting PD-L1.

What is Biological: AZD3152 used for?

Biological: AZD3152 is indicated for Non-small cell lung cancer, Head and neck squamous cell carcinoma.

Who makes Biological: AZD3152?

Biological: AZD3152 is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What drug class is Biological: AZD3152 in?

Biological: AZD3152 belongs to the PD-1/PD-L1 inhibitor class. See all PD-1/PD-L1 inhibitor drugs at /class/pd-1-pd-l1-inhibitor.

What development phase is Biological: AZD3152 in?

Biological: AZD3152 is in Phase 2.

What are the side effects of Biological: AZD3152?

Common side effects of Biological: AZD3152 include Fatigue, Nausea, Diarrhea, Rash, Pyrexia.

What does Biological: AZD3152 target?

Biological: AZD3152 targets PD-L1 and is a PD-1/PD-L1 inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing